TNBC is the most aggressive and difficult to treat breast cancer subtype, since hormone receptors (HR) are absent and the human epidermal growth factor receptor 2 (HER2) protein is not overexpressed on the surface of TNBC cells. This evidence concerns the gene HR and breast cancer.